Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Impacts of antibody cross-reactivity on gut community ecology and vaccine immunogenicity

Project description

Vaccines against antimicrobial resistant pathogens

Antimicrobial resistance (AMR) occurs when microorganisms evolve to resist the effects of antimicrobial drugs. Misuse and overuse of antimicrobial drugs exacerbate this phenomenon, rendering antimicrobials ineffective and threaten routine common procedures. Vaccines are a viable option against AMR, but we must first understand how the immune system can distinguish between harmful pathogens and beneficial gut microbes. With the support of the Marie Skłodowska-Curie Actions programme, the SUGAR project will investigate how immune responses to AMR-priority pathogens like Salmonella and Shigella may cross-react with helpful gut bacteria due to shared surface sugar structures. Project findings will guide the development of precise vaccines that combat AMR without disrupting gut health.

Objective

Antimicrobial resistance (AMR) is a looming global threat, rendering antibiotic treatments useless, and making bacterial infections difficult to treat. With diminishing antibiotic options to control infectious outbreaks, we must develop new strategies to prevent widespread mortality. Our group develops novel vaccines to leverage the body’s natural immune responses to fight bacterial infections. To do this, it is crucial to understand how our immune systems recognize harmful bacteria (“pathogens”), and how they distinguish them from the ‘good’ gut-resident microbes which promote human health. Oral vaccines typically induce protective immune responses which recognize sugar structures on the outer membrane of harmful bacteria, promoting their elimination. However, some of these sugar structures use the same molecular building blocks as those found on the surface of beneficial bacteria. In fact, some pathogens mimic the sugar structures of beneficial microbes to evade the immune system. In turn, this may lead to inappropriate recognition of good bacteria by the immune system. I plan to combine vaccination studies in mice with molecular tools to study direct surface sugar-immune interactions, focusing on immune responses to World Health Organization AMR priority pathogens Salmonella and Shigella. I will answer fundamental questions about immune-bacterial recognition: (1) Can immune antibodies induced in response to harmful pathogens also recognize good bacteria? (2) Does this recognition impact the composition and host-beneficial functions of gut resident microbial communities? (3) Does non-specificity of bacterial immune targeting reduce vaccine-mediated protection? Outcomes will contribute to fundamental scientific knowledge of immune-bacterial interactions and provide valuable public health insights, including explaining individual variation in vaccine protectiveness. Ultimately, this work will inform the design of effective human vaccines to combat AMR.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-TMA-MSCA-PF-EF - HORIZON TMA MSCA Postdoctoral Fellowships - European Fellowships

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-MSCA-2024-PF-01

See all projects funded under this call

Coordinator

THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD
Net EU contribution
€ 260 347,92
Address
WELLINGTON SQUARE UNIVERSITY OFFICES
OX1 2JD Oxford
United Kingdom
Region
South East (England) Berkshire, Buckinghamshire and Oxfordshire Oxfordshire
Activity type
Higher or Secondary Education Establishments
Links
Total cost
No data